Connection
William Fantegrossi to Cannabinoid Receptor Antagonists
This is a "connection" page, showing publications William Fantegrossi has written about Cannabinoid Receptor Antagonists.
|
|
Connection Strength |
|
|
|
|
|
0.802 |
|
|
|
-
Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Drug Alcohol Depend. 2018 11 01; 192:285-293.
Score: 0.645
-
Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. J Med Chem. 2013 Jun 13; 56(11):4537-50.
Score: 0.111
-
Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. Pharmacol Biochem Behav. 2020 08; 195:172949.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|